u/rohan_cardoso

A quoted lead time is a commitment you can evaluate. Measuring quoted against actual across several orders tells you more about an operation than the raw speed does.

A lane is an origin, a destination, a carrier and a season. Change any one and the distribution changes, which is why supplier-level shipping averages are close to meaningless.

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

a press release is not a publication

Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.

Yes — median rather than best case. The fastest anybody ever got is not a plan.

Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use, and that is a statement of fact rather than a disclaimer.

A lane is an origin, a destination, a carrier and a season.

Disagreeing with this bit: a single slow shipment does not move a lane, it joins the distribution.

Yes — regional stock is the single biggest variable and it barely gets mentioned outside this board.

Not convinced.

Adding the standing caveat: none of this is approved anywhere and research material is not for human use.

Split one order across two months on purpose to compare summer and winter. Four days apart, same carrier, same route.

Correction: TRIUMPH is the phase 3 programme.

reflux_report is right about the escalation being the variable. It explains most of the difficult reports here.

I would not read a single slow shipment as a lane change. Post it and let the median move if it is real.

Yes — the glucagon arm is what makes it a different proposition rather than a stronger version of the others.

phase 2 data only, and people quote it like it is a label

ask which lines are actually held in the regional warehouse

Sent a vial to VendorInvestigate out of curiosity. Result was 97.7% against a claimed 97.5%, which is the first independent number I had seen for this compound anywhere.

The thing that surprised me was how much of the discussion here is inference rather than measurement.

regain after stopping is the expected outcome, not a personal failure

a mean is not a promise

Agreed. And the interval, not the point estimate, is what the trial actually established.

The press release said that; the publication says something more hedged. Worth reading both.

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

the lane is the unit of analysis, not the supplier

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

Agreed that a few kilos of drift is ordinary. Weight is not a fixed number even for people who have never taken anything.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

a few kilos of drift is not a relapse

the lowest effective dose is a real target and nobody talks about it

Sent a vial to Medutest out of curiosity. Result was 97.2% against a claimed 97.0%, which is the first independent number I had seen for this compound anywhere.

SELECT was cardiovascular outcomes, not weight

Which trial, and which arm?

That is a packaging observation, not a transit observation. Worth posting, worth separating.

Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.

small trial, big effect, wide error bars

Careful — the supplier does not control the last mile and most of your variance is in it.

Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.